Basilisk (BSX) news

Boston Scientific's WATCHMAN FLX Pro trial meets primary endpoints

Penumbra Q3 net income falls 8% to $42.28 million; Q3 revenue rises 16% to $410.15 million

UBS Adjusts Boston Scientific Price Target to $57 From $67, Maintains Buy Rating

BOSTON SCIENTIFIC CORPORATION <BSX.N>: UBS CUTS TARGET PRICE TO $57 FROM $67

BOSTON SCIENTIFIC CORP. <BSX.N>: OPPENHEIMER CUTS TO PERFORM FROM OUTPERFORM

BOSTON SCIENTIFIC CORPORATION <BSX.N>: LEERINK PARTNERS CUTS TARGET PRICE TO $50 FROM $55

BOSTON SCIENTIFIC <BSX.N>: DEUTSCHE BANK CUTS TARGET PRICE TO $48 FROM $60

BOSTON SCIENTIFIC CORPORATION <BSX.N>: WELLS FARGO CUTS TARGET PRICE TO $45 FROM $48

Citi lowers Boston Scientific’s target price to $44

BOSTON SCIENTIFIC CORPORATION <BSX.N>: CITIGROUP CUTS TARGET PRICE TO $44 FROM $48

BOSTON SCIENTIFIC CORPORATION <BSX.N>: JEFFERIES CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $46 FROM $60

BOSTON SCIENTIFIC CORPORATION <BSX.N>: BTIG CUTS TARGET PRICE TO $49 FROM $56

BOSTON SCIENTIFIC CORPORATION <BSX.N>: PIPER SANDLER CUTS TARGET PRICE TO $55 FROM $60

BOSTON SCIENTIFIC CORPORATION <BSX.N>: NEEDHAM CUTS TARGET PRICE TO $48 FROM $57

BOSTON SCIENTIFIC CORPORATION <BSX.N>: JP MORGAN CUTS TO NEUTRAL FROM OVERWEIGHT; CUTS TARGET PRICE TO $46 FROM $56

Update: S&P 500, Nasdaq Rise For Third Day Following Fed Pause

Boston Scientific Corp. Stock Slides 5.8%, Underperforms Peers

Sector Update: Healthcare Stocks Rise Late Afternoon

U.S. Stock Market: The Federal Reserve Maintains Interest Rates, Rate Hike Expectations Postponed to December, Wall Street Stocks Rise Broadly

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Update: Equities Rise Intraday as Fed Decision Looms

Boston Scientific warns of facing severe challenges in 2027 due to weak pricing in the Chinese market and sluggish cardiac device business.

Top Midday Stories: GE Vernova to Acquire Trench Group for $9 Billion; Wendy's Receives $1.4 Billion Takeover Offer From Trian-Led Group

Boston Scientific Lowers Full-Year Outlook Amid Cyberattack Impact

US Stock Market - Ahead of the Federal Reserve's decision, Wall Street fluctuates as declines in mega-cap stocks offset gains in chip stocks

Boston Scientific works to restore operations after August cybersecurity incident

Stocks Mostly Up Pre-Bell Ahead of Fed Policy Decision, Key Tech Earnings

Boston Scientific Q3 Adjusted Earnings Fall, Revenue Rises

Boston Scientific forecasts Q4 2026 net sales decline of 1%-3%

Boston Scientific Q3 net income attributable to common stockholders falls 23% to $582 million